Posted on 9/11/17
Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.
By late June, Cara Therapeutics, Inc. (NASDAQ:CARA) stock had soared more than 175% year to date. Within a couple of weeks, however, many of those gains . . .
Posted on 9/11/17
Is Amicus Therapeutics Stock Still a Strong Buy?
What happenedAccording to data from S&P Global Market Intelligence, shares of rare-disease drugmaker Amicus Therapeutics (NASDAQ:FOLD) rose by 6.6% last month. Although the company did provide . . .
Posted on 9/10/17
Johnson & Johnson: (Some) More Room To Go
J&J has picked up 14% since we recommended it early this year, driven by strong execution and optimism regarding a recent acquisition that could buttress its . . .
Posted on 9/8/17
Thoughts On Celgene Rising Despite Negative News Today
Introduction - Celgene not as strong as Hurricane Irma, but pretty strong nonethelessThe biotech I have championed most strongly for the past 11 months, Celgene (NASDAQ:CELG), . . .
Posted on 9/7/17
Promius Pharma Named PM360 Trailblazer 2017 Company of the Year
PM360, a publication for marketing decision-makers in the pharmaceutical, biotech, and medical device industries, recently named Promius Pharma LLC as a finalist for the Trailblazer Company . . .
Posted on 9/6/17
Mid-Atlantic Dental Partners Raises $12.5 Million
Mid-Atlantic Dental Service Holdings LLC, operating as Mid-Atlantic Dental Partners, a dental support organization
Posted on 9/6/17
Progenics FDA Delay Is Just A Flesh Wound
Recently, Progenics Pharmaceuticals (PGNX) announced that it would have to delay its New Drug Application (NDA) to the FDA. The reason being is that its third-party . . .
Posted on 9/5/17
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Two of the biggest pharmaceutical companies in the world have been around since the 19th century. Eli Lilly and Company (NYSE:LLY) was founded in 1876, while . . .
Posted on 9/4/17
Johnson & Johnson: How Does An $11 Special Dividend Sound To You?
The price Johnson & Johnson (JNJ) paid for acquiring Actelion has most likely been a bit too high and destroyed shareholder wealth.Even through the acquisition of . . .
Posted on 9/4/17
Acorda Adopts Shareholder Rights Plan
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that its Board of Directors has adopted a Shareholder Rights Plan, effective September 1, 2017, and declared . . .
Posted on 9/1/17
Pfizer's FCF And Dividend Implications
Photo creditPfizer (PFE) – like its mega-cap pharma brethren – has long been reliant upon capital returns to satisfy shareholders. The dividend is huge at nearly . . .
Posted on 9/1/17
What About A Bristol-Myers Squibb Takeover By Pfizer?
Pfizer (PFE) has a history of making big acquisitions, and has access to very cheap cash right now -- this would allow the company to make . . .
Posted on 9/1/17
Why Teva Pharmaceutical Industries, Shoe Carnival, and Hasbro Jumped Today
The major benchmarks all moved higher Thursday, with the Nasdaq Composite producing the biggest gains. The growing devastation left in the wake of Hurricane Harvey still . . .
Posted on 8/31/17
Celgene Has Led Bluebird Into A Crowded Field
Two years ago, when Lenti-D and LentiGlobin were still its lead product candidates, I viewed bluebird bio (BLUE) as industry leader in the development of gene . . .
Posted on 8/31/17
Merck's Growth Catalyst
Photo creditMerck (MRK) shares have been stuck in neutral for some time as the company’s growth rates haven’t been enough to spur buyer interest. Of course, . . .
Posted on 8/31/17
Merck: Keytruda As A Growth Driver
Merck (MRK) has been struggling to drive top-line growth for years, resulting in a lack of growth of its share price as well. But now, its . . .
Posted on 8/31/17
Celgene Continues Support In Latest Financing Round For ARMO BioSciences
Quick TakeBiopharmaceutical company Celgene (CELG) has participated in the $67 million Series C-1 financing round of ARMO BioSciences.ARMO is a clinical stage company developing a pipeline . . .
Posted on 8/30/17
American Health Council Honors Sandra Kaufmann, MD as America’s Best Doctor
NEW YORK, Aug. 30, 2017 (GLOBE NEWSWIRE) -- As Chief of Pediatric Anesthesia at Joe DiMaggio Children’s Hospital and Sheridan Health Corporation, Dr. Sandra Kaufmann is . . .
Posted on 8/30/17
Axsome Therapeutics Sweetens The Deal For Investors
Axsome Therapeutics (AXSM) is a biopharmaceutical company with multiple Phase 3 trials nearing interim data readouts, a market cap of approximately $112 million, and cash anticipated . . .
Posted on 8/30/17
Immune Pharmaceuticals Receives NASDAQ Letter
NEW YORK--(BUSINESS WIRE)--Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that on August 23, 2017, the Company received written notice from the Listing Qualifications Department of The . . .
Posted on 8/28/17
Immune Pharmaceuticals Provides R&D and Business Update
NEW YORK--(BUSINESS WIRE)--Immune Pharmaceuticals Inc. (NASDAQ:IMNP) provided the following R&D and business update and summary of recent financial highlights.R&D UpdateImmune continues to focus on the development . . .
Posted on 8/28/17
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Boston Pharmaceuticals, Inc. (hereafter, Boston Pharmaceuticals) today announced they have entered into a worldwide licensing agreement for Daiichi . . .
Posted on 8/28/17
Merck: Shareholders Will Fail To Be Rewarded Here
Investment ThesisMerck (MRK) has truly great prospect with its Keytruda program, but its shares are just too expensive at the moment.Business Prospects: KeytrudaMerck's Keytruda is a . . .
Posted on 8/26/17
Zelis Healthcare Recognized for Seventh Year on Prestigious Inc. 5000
BEDMINSTER, N.J.--(BUSINESS WIRE)--For the seventh time, Zelis Healthcare has earned recognition on Inc. Magazine’s Inc. 5000, the most prestigious ranking of the nation's fastest-growing private companies. . . .
Posted on 8/25/17
GPB Capital Acquires Four Physical Therapy Center Operators
GPB Capital has established a presence in the healthcare industry through acquisitions of four physical therapy center

